Latest news-Research-BIO CENTER

Abandons Quick Fixes for Fundamental Elements, Specializing in Structural Targeted Efficacy with Sustained-Release Time Repair

2026-02-04

Rational Era - When Male Consumption Enters the "Evidence-Driven" Age

Focusing on Systemic Cellular Anti-Aging: Reignite Vitality at the Source

2025-07-15

LIFESUGI (Baisheng Tai 4th Generation) is a systemic cellular anti-aging oral dietary supplement developed under North American BIOCENTER. Jointly researched and developed by BIOCENTER in collaboration with the NAD+ Metabolism Laboratory at Harvard Medical School and the Japan Institute of Biomedical Research, this product leverages liposomal nano-encapsulation technology and a multi-target synergistic formula to establish a systemic anti-aging matrix encompassing “Energy – Repair – Circulation – Neurology.”

MICROBIAL BALANCE METABOLISM WITH NO SIDE EFFECTS ON ACID CONTROL

2025-06-04

MetRushPro is BIOCENTER's new scientific metabolic regulation supplement. Through the whole-process intervention of "enzyme inhibition → flora regulation → uric acid excretion → crystallization dissolution, inflammation alleviation, metabolism repair, and organ protection", MetrushPro can achieve targeted improvement of high uric acid, metabolic retardation and other problems. To meet the long-term metabolic management needs of contemporary hypertensive population.

FDA Approves First Nasal Spray for Emergency Allergic Reactions

2024-08-23

On August 9, 2024, the U.S. Food and Drug Administration (FDA) approved Neffy, an epinephrine nasal spray developed by ARS Pharmaceuticals, for the emergency treatment of type I allergic reactions in adults and children weighing at least 30 kg. This marks the first non-injection epinephrine product approved by the FDA.

First Non-Addictive Painkiller Application Submitted in 20 Years

2024-08-22

On August 20, 2024, Scientific American reported that Vertex Pharmaceuticals (VRTX.US) has developed a novel painkiller capable of reducing acute pain levels by approximately 50% without the risk of addiction. On July 30, 2024, Vertex announced that the U.S. Food and Drug Administration (FDA) had accepted a New Drug marketing application for the drug and granted priority review status. The drug, VX-548, is used to treat moderate to severe acute pain. If approved, VX-548 will be the first non-opioid acute pain medication to hit the market in two decades, marking a significant milestone in pain management.

AAV Gene Therapy: A Potential Breakthrough for Rare Disease Treatment

2024-08-12

Seven-year-old Canadian child Michael Piravola was diagnosed with a mutation in his AP4M1 gene at just 18 months old. By the age of two, he was diagnosed with hereditary spastic paraplegia type 50, an ultra-rare condition characterized by developmental delays, microcephaly, speech impairments, and limitations in standing and walking.

New Drug Shows Promise in Clearing HIV from the Brain

2024-07-29

A recent study conducted by Tulane University suggests that an experimental drug, originally developed for cancer treatment, may have the potential to eliminate HIV from infected cells in the brain. Researchers at the Tulane National Primate Research Center have discovered that an anti-cancer drug significantly reduced the levels of SIV (Simian Immunodeficiency Virus) in the brain by targeting and depleting specific virus-carrying immune cells. SIV is the equivalent virus to HIV. This finding, published in the journal Brain, represents a significant advancement in the effort eliminate HIV from difficult-to-reach viral reservoirs.

Receptor Density Affects Circadian Rhythms in the Biological Clock

2024-07-26

Researchers at Washington University in St. Louis are delving into the mechanisms of the human biological clock and how it keeps time. Their latest findings, published on July 24 in the Proceedings of the National Academy of Sciences, shed light on longstanding questions about the generation and maintenance of circadian rhythms.